Press releasePRNewswire
Decoy Therapeutics
DCOY · NASDAQ
$1.14−$0.035 (−2.99%)TodayMarket closed ·
Prev close $1.17
Latest news
- Press releasePRNewswire
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
- NewsAvi Kapoor
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
- Press releasePRNewswire
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
- Press releaseGlobe Newswire
Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals
- NewsAvi Kapoor
Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings
- News
Decoy Therapeutics Announces Its Exploring Non-Dilutive Federal Grants, Public Health Collaborations To Support Preclinical, Clinical Development Of Biodefense Pipeline
- Press releasePRNewswire
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
- Press releasePRNewswire
/C O R R E C T I O N -- Decoy Therapeutics, Inc/
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
- Press releasePRNewswire
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releasePRNewswire
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
- NewsAvi Kapoor
Crude Oil Gains 2%; Comcast Shares Spike Higher
- NewsDylan Berman
Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing
- Press releaseGlobe Newswire
4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
- News
Market-Moving News for June 29th
- Press releasePRNewswire
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
- Press releasePRNewswire
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
- Press releasePRNewswire
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
- Press releasePRNewswire
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
- Press releasePRNewswire
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releasePRNewswire
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
- Press releasePRNewswire
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
- Press releasePRNewswire
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
- Press releasePRNewswire
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Press releasePRNewswire
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
- Press releasePRNewswire
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
- Press releasePRNewswire
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
- Press releasePRNewswire
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
- Press releasePRNewswire
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.